Basic Information
LncRNA/CircRNA Name | ANRIL |
Synonyms | CDKN2B-AS1, ANRIL, CDKN2B-AS, CDKN2BAS, NCRNA00089, PCAT12, p15AS |
Region | GRCh38_9:21994778-22121097 |
Ensemble | ENSG00000240498 |
Refseq | NR_003529 |
Classification Information
Regulatory Mechanism | Biological Function | Clinical Application | |||
---|---|---|---|---|---|
TF | Immune | Survival | |||
Enhancer | Apoptosis | apoptosis | Drug | ||
Variant | Cell Growth | Circulating | |||
MiRNA | EMT | Metastasis | |||
Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
Cancer Name | non small cell lung cancer |
ICD-0-3 | C34 |
Methods | qPCR, RNAi, Western blot, Luciferase reporter assay etc. |
Sample | NSCLC tissues, cell lines (SK-MES-1, A549, SPC-A1, and NCI-H1975) |
Expression Pattern | up-regulated |
Function Description | The high expression level of ANRIL was positively correlated with advanced tumor-node-metastasis stage and greater tumor diameter. Furthermore, chromatin immunoprecipitation assays confirmed the physical interaction between c-Myc and ANRIL. ANRIL silencing significantly inhibited NSCLC cell proliferation. |
Pubmed ID | 27307748 |
Year | 2016 |
Title | Long noncoding RNA ANRIL could be transactivated by c-Myc and promote tumor progression of non-small-cell lung cancer. |
External Links
Links for ANRIL | GenBank HGNC NONCODE |
Links for non small cell lung cancer | OMIM COSMIC |